4//SEC Filing
Warren Russell F JR 4
Accession 0001104659-08-078452
CIK 0000883697other
Filed
Dec 23, 7:00 PM ET
Accepted
Dec 24, 5:10 PM ET
Size
8.4 KB
Accession
0001104659-08-078452
Insider Transaction Report
Form 4
Warren Russell F JR
10% Owner
Transactions
- Purchase
Option
2007-03-30+238,095→ 238,095 totalExercise: $8.40→ Common Stock (238,095 underlying)
Holdings
- 27,500
Common Stock
- 526,345
Common Stock
Footnotes (3)
- [F1]The reported securities are held by Ivy Healthcare Capital II, L.P. Russell F. Warren, Jr., principal of Ivy Healthcare Capital II, L.P., has shared voting and dispositve control of the reported securities. Mr. Warren disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F2]On December 22, 2008, the Issuer issued a press release relating to the recent U.S. Food and Drug Administration ("FDA") clearance to market its collagen scaffold device. Such FDA clearance resulted in the exercisability of Ivy Healthcare's options to acquire 238,095 shares of common stock pursuant to the Option Agreement dated March 30, 2007 by and between ReGen Biologics, Inc. and Ivy Healthcare (the "Option Agreement"). Pursuant to the terms of the Option Agreement, the option must be exercised, if at all, within 15 calendar days of the public announcement of FDA clearance.
- [F3]The option was issued pursuant to the Option Agreement and in conjunction with a subscription agreement by and between ReGen Biologics, Inc. and each of the investors named therein dated March 30, 2007 (the "Subscription Agreement"). Each investor purchased Series D Preferred Stock of ReGen Biologics, Inc. at $42 per share. Without additional consideration, ReGen Biologics entered into an option agreement with each of the investors.
Documents
Issuer
REGEN BIOLOGICS INC
CIK 0000883697
Entity typeother
Related Parties
1- filerCIK 0001413434
Filing Metadata
- Form type
- 4
- Filed
- Dec 23, 7:00 PM ET
- Accepted
- Dec 24, 5:10 PM ET
- Size
- 8.4 KB